Aditxt, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 04:31 pm EDT
Share
Aditxt, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.220978 million compared to USD 0.214715 million a year ago. Net loss was USD 5.68 million compared to USD 5.85 million a year ago. Basic loss per share from continuing operations was USD 36.8 compared to USD 256.8 a year ago.
For the six months, sales was USD 0.439393 million compared to USD 0.424994 million a year ago. Net loss was USD 11.67 million compared to USD 11.91 million a year ago. Basic loss per share from continuing operations was USD 86.8 compared to USD 528.4 a year ago.
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
ADITXT, INC. 
